ENTX
NASDAQEntera Bio Ltd.
News · 26 weeks55+233%
2026-03-012026-08-23
Mix3390d
- Insider11(33%)
- Other10(30%)
- SEC Filings10(30%)
- Offering1(3%)
- Leadership1(3%)
Latest news
25 items- SECSEC Form S-3 filed by Entera Bio Ltd.S-3 - Entera Bio Ltd. (0001638097) (Filer)
- INSIDERSEC Form 3 filed by new insider Camisasca Riccardo Paolo3 - Entera Bio Ltd. (0001638097) (Issuer)
- SECEntera Bio Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Other Events8-K - Entera Bio Ltd. (0001638097) (Filer)
- PREntera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 InitiationDr. Camisasca joins Entera with 30 years of global pharmaceutical research and clinical development experience including roles at Sumitomo Pharma, Takeda, and Novartis Appointment further strengthens Entera’s clinical execution team and late-stage development capabilities ahead of planned EB613 Phase 3 initiation TEL AVIV, Israel, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced the appointment of Riccardo Paolo Camisasca, M.D., as Chief Medical Officer. Dr. Camisasca is a physician, clinical pharmacologist and global pharmaceutical executive with more than 30 years of experience spa
- SECSEC Form D filed by Entera Bio Ltd.D - Entera Bio Ltd. (0001638097) (Filer)
- INSIDERDirector Rubin Steven D was granted 19,117 units of Ordinary Shares, increasing direct ownership by 127% to 34,117 units (SEC Form 4)4 - Entera Bio Ltd. (0001638097) (Issuer)
- INSIDERDirector Malca Yonatan was granted 22,815 units of Ordinary Shares, increasing direct ownership by 29% to 100,231 units (SEC Form 4)4 - Entera Bio Ltd. (0001638097) (Issuer)
- INSIDERDirector Taitel Haya was granted 20,790 units of Ordinary Shares, increasing direct ownership by 21% to 119,269 units (SEC Form 4)4 - Entera Bio Ltd. (0001638097) (Issuer)
- INSIDERDirector Ellis Sean was granted 20,034 units of Ordinary Shares, increasing direct ownership by 11% to 208,132 units (SEC Form 4)4 - Entera Bio Ltd. (0001638097) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Yaacov-Garbeli Dana4 - Entera Bio Ltd. (0001638097) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Galitzer Hillel4 - Entera Bio Ltd. (0001638097) (Issuer)
- INSIDERSEC Form 4 filed by Chief of R&D Burshtein Gregory4 - Entera Bio Ltd. (0001638097) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Toledano Miranda Jayne4 - Entera Bio Ltd. (0001638097) (Issuer)
- INSIDERDirector Germano Geno J was granted 25,014 units of Ordinary Shares, increasing direct ownership by 63% to 65,014 units (SEC Form 4)4 - Entera Bio Ltd. (0001638097) (Issuer)
- SECSEC Form S-8 filed by Entera Bio Ltd.S-8 - Entera Bio Ltd. (0001638097) (Filer)
- SECSEC Form 10-Q filed by Entera Bio Ltd.10-Q - Entera Bio Ltd. (0001638097) (Filer)
- SECEntera Bio Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Entera Bio Ltd. (0001638097) (Filer)
- PREntera Announces Second Quarter 2026 Financial Results and Business UpdatesU.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis Oversubscribed $275 Million Private Placement Led by BVF Partners L.P. ("BVF") with Participation from Leading Institutional Healthcare Investors to Fund EB613 through Anticipated Submission of NDA to the FDA EB613 Phase 3 Study Initiation Planned for Late 2026 with Topline Data Anticipated in the Second Half of 2028 IND Enabling Studies Ongoing for EB612 - the First Oral Peptide Replacement Tablet in Development for Patients with Hypoparathyroidism – Intention to File IND in First Hal
- SECSEC Form SCHEDULE 13D filed by Entera Bio Ltd.SCHEDULE 13D - Entera Bio Ltd. (0001638097) (Subject)
- PREntera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual MeetingTEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that post-hoc data from its Phase 2 clinical trial of EB613 (oral PTH(1-34) tablet) has been selected for two presentations including the Plenary Poster Presentation at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9–12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts. Plenary Posters are highly ranked poster presentations selected by the ASBMR program committee to be presented at the Welcome Reception and Plenary Poster Session of th
- PREntera Bio to Participate in the Canaccord Genuity 46th Annual Growth ConferenceTEL AVIV, July 31, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be participating in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference, details as below. Canaccord Genuity 46th Annual Growth Conference (Fireside Chat and 1x1 Meetings) Date and Time: August 12, 2026 at 1:00 p.m. Eastern TimeLocation: In person, August 11–13, 2026, InterContinental Boston Hotel, 510 Atlantic Avenue, Boston, MAWebcast: https://event.summitcast.com/view/WuFmFdTcA9mVsUGHZJFU62/3r4fss8AzFCZNhJDzPz9Sa A live webcast of the di
- PRGreenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPEMIAMI, July 29, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides, in connection with its oversubscribed $275 million private placement financing. The financing is expected to extend Entera Bio's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first oral PTH (1-34) peptide tablet in development for the treatment of osteoporosis, according to the company's press release.This financing is the largest publicly disclosed Israeli biotech private investment in public equity (PIPE) on record and the nint
- SECEntera Bio Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits8-K - Entera Bio Ltd. (0001638097) (Filer)
- PREntera Bio Announces Pricing of Oversubscribed $275 Million Private PlacementThe offering is led by existing investor BVF Partners L.P. Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first oral PTH(1-34) peptide tablet in development for the treatment of osteoporosis TEL AVIV, July 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that it has entered into a securities purchase agreement (the "Purchase Agreement") for an oversubscribed private placement financing (the "Private Placement"). The Private Placement is expected to result in aggregate gross proceeds to
- SECEntera Bio Ltd. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year8-K - Entera Bio Ltd. (0001638097) (Filer)
ENTX FAQ
6 questionsWhat does Entera Bio Ltd. do?
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc...Where does ENTX stock trade?
Entera Bio Ltd. (ENTX) is listed on NASDAQ.What sector and industry is ENTX in?
Entera Bio Ltd. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Entera Bio Ltd. go public?
Entera Bio Ltd. (ENTX) completed its IPO in 2018.What companies are similar to ENTX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare ENTX side-by-side with any of them on Quantisnow.How can I track ENTX on Quantisnow?
Quantisnow aggregates Entera Bio Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ENTX to receive live email and push alerts on every new disclosure.